ISU Abxis KRX:086890KOSDAQ
이수앱지스 · Korean news coverage and regulatory filings, organized.
In Q3 2026, ISU Abxis reported revenue of ₩9.4bn, down 40.5% year on year, and an operating loss of ₩6.3bn. ISU Abxis (이수앱지스) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 9 with 8 articles. The most common catalyst was earnings (1). It was most often mentioned alongside D&D Pharmatech and Peptron.
Filing signals Swung to loss Screener
ISU Abxis today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates ISU Abxis stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
ISU Abxis quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩9.4bn | -40.5% | −₩6.3bn margin −67.4% | −₩8.6bn |
| Q2 2026 | ₩14.9bn | -34.6% | ₩479m margin 3.2% | ₩3.2bn |
| Q1 2026 | ₩9.5bn | +31.6% | −₩3.4bn margin −36.4% | −₩202m |
| Q4 2025 derived | ₩10.9bn | -47.1% | −₩7.8bn margin −71.8% | −₩10.9bn |
| Q3 2025 | ₩15.7bn | +79.5% | ₩562m margin 3.6% | −₩255m |
| Q2 2025 | ₩22.8bn | +59.2% | ₩9.4bn margin 41.1% | ₩9.2bn |
| Q1 2025 | ₩7.2bn | -56.5% | −₩463m margin −6.5% | −₩8.8bn |
| Q4 2024 derived | ₩20.6bn | +24.7% | ₩5.3bn margin 25.4% | ₩27.9bn |
ISU Abxis ranks #2247 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
ISU Abxis top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest ISU Abxis news Korean headlines
-
IS AppJis posts 6.3 billion won operating loss in Q3…affected by delayed overseas sales and inventory losses
1 more on this story · 1 outlets
-
Isua Apgis exports Fabagal to Peru for first time, expands overseas strategy for rare disease treatments
2 more on this story · 2 outlets
-
Isua Apgis expands overseas markets with Fabagal and Abestatine, targeting Central and South America, Middle East and Africa
1 more on this story · 1 outlets
- Isua Apgis steps up overseas market strategy with Fabagal and Abestatine프라임경제 · Sep 21 09:35